INVEST PharmaTech Pitch Perfect virtual conference July 26 will give startups the opportunity to present their approaches to clinical trial innovation to a team of investor judges. Apply today!
In the runup to MedCity INVEST in Chicago, we're spotlighting the perspectives of investors and what motivates them to invest in startups. If you're a startup in pharma tech, value-based care and care coordination, diagnostics or remote patient monitoring/smart devices, apply to our Pitch Perfect contest today.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
If you're a startup focused on population health, addressing social determinants of health, or helping people manage chronic diseases, you should apply by October 22.
Who made the finals for this INVEST Digital Health Pitch Perfect track? Read about these digital health companies and check out the virtual event from September 20-23. Register today!
Read more to find out which finalists will present in the startup pitch contest during the conference, which will be virtual, and is scheduled for September 20-23.
The startup pitch contest is part of our INVEST conference, April 19-23, which will be hosted online due to the Covid-19 public health crisis. It includes five tracks for startups: biopharma, medical devices, diagnostics, health IT and health services.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Apply to the startup pitch contest if you belong to any one of the following healthcare verticals – biopharma, medical devices, diagnostics, health IT or health services. The deadline to apply is 5pm ET, Friday, January 15.
All startups are invited to apply for our annual INVEST Pitch Perfect Contest that will take place virtually as part of our annual INVEST conference in April next year.
The Silicon Valley startup plans to start its registration-directed study of Limbix Spark in the earlier part of next year and - if successful - would anticipate FDA clearance in early 2022.
The company is developing a form of asparaginase - widely used to treat certain cancers - designed to overcome the toxicity associated with the drug.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The company is one-twelfth of the way into a $600,000 seed round and hopes to begin clinical testing of its Valkyrie device in late 2019 or early 2020.
Moving Analytics is a startup trying to address socio-economic factors that make it difficult to complete rehab in a traditional brick-and-mortar facility through a tech-enabled home rehab system.